The interplay of gut microbiota, obesity, and depression: insights and interventions
The gut microbiome, body weight, and related comorbidities are intricately linked through a
complex interaction of microbial, genetic, environmental, and psychological factors …
complex interaction of microbial, genetic, environmental, and psychological factors …
A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment
M Tobaiqy - Pharmacological Reports, 2024 - Springer
Abstract Glucagon-like peptide-1 (GLP-1) agonists play a crucial role in treating type 2
diabetes mellitus and obesity by providing glycemic control and aiding weight management …
diabetes mellitus and obesity by providing glycemic control and aiding weight management …
Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality
Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained use
primarily due to their weight-reduction effects, although a regulatory review was undertaken …
primarily due to their weight-reduction effects, although a regulatory review was undertaken …
Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials
Importance Obesity is associated with numerous psychosocial complications, making
psychiatric safety a consideration for treating people with obesity. Few studies have …
psychiatric safety a consideration for treating people with obesity. Few studies have …
Risk of Suicidal Ideation or Attempts in Adolescents With Obesity Treated With GLP1 Receptor Agonists
L Kerem, J Stokar - JAMA pediatrics, 2024 - jamanetwork.com
Importance Glucagon-like peptide 1 receptor agonists (GLP1R) are increasingly being used
for the treatment of obesity in adolescents. It is currently unknown whether GLP1R treatment …
for the treatment of obesity in adolescents. It is currently unknown whether GLP1R treatment …
[HTML][HTML] Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life
A Shchendrygina, A Rakisheva, I Giverts… - Cardiac Failure …, 2024 - pmc.ncbi.nlm.nih.gov
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are emerging glucose-lowering
agents primarily used in managing diabetes and obesity. Recently, GLP-1 RAs have …
agents primarily used in managing diabetes and obesity. Recently, GLP-1 RAs have …
[HTML][HTML] Association between symptoms of depression and generalised anxiety disorder evaluated through PHQ-9 and GAD-7 and anti-obesity treatment in Polish …
T Witaszek, K Kłoda, A Mastalerz-Migas, M Babicki - Nutrients, 2024 - mdpi.com
Obesity impacts mental health greatly. Psychological factors may influence the effectiveness
of its treatment. This study aimed to compare symptoms of generalised anxiety disorder and …
of its treatment. This study aimed to compare symptoms of generalised anxiety disorder and …
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
S Tempia Valenta, A Nicastri, F Perazza… - … Treatment Options in …, 2024 - Springer
Purpose Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for
managing metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity. Beyond …
managing metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity. Beyond …
Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications
L Moss, M Laudenslager, KJ Steffen… - Current Obesity …, 2025 - Springer
Abstract Purpose of Review To highlight recent research on antidepressant use and weight
change and explore best clinical practices for reducing weight gain and obesity risk in …
change and explore best clinical practices for reducing weight gain and obesity risk in …
Association of GLP1R locus with mental ill‐health endophenotypes and cardiometabolic traits: A trans‐ancestry study in UK Biobank
MME Hayman, W Jones, A Aman… - Diabetes, Obesity …, 2024 - Wiley Online Library
Aims Glucagon‐like peptide 1 receptor agonists (GLP1RA), used to treat type 2 diabetes
and obesity, have been associated with off‐target behavioural effects. We systematically …
and obesity, have been associated with off‐target behavioural effects. We systematically …